Lymphocytic choriomeningitis virus (LCMV) infection of macaques: A model for Lassa fever

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 125-138

  Zapata, Juan C ^a   Pauza, C David ^a   Djavani, Mahmoud M ^a   Rodas, Juan D ^b   Moshkoff, Dmitry ^a   Bryant, Joseph ^a   Ateh, Eugene ^a   Garcia, Cybele ^c   Lukashevich, Igor S ^a   Salvato, Maria S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Arenaviruses; Lassa fever virus; LCMV; Monkey models; Rhesus macaques; Viral hemorrhagic fever

Indexed keywords

1 (5 CHLORO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALANINE AMINOTRANSFERASE; ANGIOPEPTIN; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BAVITUXIMAB; BENZIMIDAZOLE; BRYOSTATIN; ETANERCEPT; F 100G 5; FAVIPIRAVIR; GENISTEIN; INTERLEUKIN 6; ISONIAZID; LJ 001; METHYL BETA CYCLODEXTRIN; MONOCLONAL ANTIBODY; OCTREOTIDE; RIBAVIRIN; ROFECOXIB; ST 193; ST 294; TELMISARTAN; THALIDOMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARENAVIRUS INFECTION; BLEEDING; BLOOD CLOTTING DISORDER; CAPILLARY LEAK SYNDROME; CHLOROCEBUS; DEHYDRATION; ERYTHEMA; GENE EXPRESSION; HEADACHE; HEART ARREST; HISTOPATHOLOGY; HOST; HUMAN; HYPERTRANSAMINASEMIA; INFLAMMATORY INFILTRATE; INFLUENZA; LASSA FEVER; LIVER NECROSIS; LUNG EDEMA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOCYTIC INFILTRATION; MACACA; MACACA MULATTA; MUSCLE STIFFNESS; NAUSEA; NONHUMAN; PETECHIA; PHOTOPHOBIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RHESUS MONKEY; SEROPREVALENCE; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; VIRUS HEMORRHAGIC FEVER; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; ARENAVIRIDAE INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; LASSA FEVER; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACACA MULATTA;

LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACACA; MACACA MULATTA; PRIMATES;

EID: 84860389639     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.015     Document Type: Review

References (188)

1. Adair C.V., Gauld R.L., Smadel J.E. Aseptic meningitis, a disease of diverse etiology: clinical and etiologic studies on 854 cases. Ann. Intern. Med. 1953, 39:675-704.
2. Ahmed R., Salmi A., Butler L.D., Chiller J.M., Oldstone M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 1984, 160:521-540.
3. Albarino C.G., Palacios G., Khristova M.L., Erickson B.R., Carroll S.A., Comer J.A., Hui J., Briese T., St George K., Ksiazek T.G., Lipkin W.I., Nichol S.T. High diversity and ancient common ancestry of lymphocytic choriomeningitis virus. Emerg. Infect. Dis. 2010, 16:1093-1100.
4. Armstrong C., Lillie R.D. Experimental LCM of monkeys and mice produced by a virus encountered in studies of the 1933 Saint Louis encephalitis epidemic. Public Health Rep. 1934, 49:p1019-p1027.
5. Artuso M.C., Ellenberg P.C., Scolaro L.A., Damonte E.B., Garcia C.C. Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res. 2009, 84:31-37.
6. Avila M.M., Samoilovich S.R., Laguens R.P., Merani M.S., Weissenbacher M.C. Protection of Junin virus-infected marmosets by passive administration of immune serum: association with late neurologic signs. J. Med. Virol. 1987, 21:67-74.
7. Baas T., Baskin C.R., Diamond D.L., Garcia-Sastre A., Bielefeldt-Ohmann H., Tumpey T.M., Thomas M.J., Carter V.S., Teal T.H., Van Hoeven N., Proll S., Jacobs J.M., Caldwell Z.R., Gritsenko M.A., Hukkanen R.R., Camp D.G., Smith R.D., Katze M.G. Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J. Virol. 2006, 80:10813-10828.
8. Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debre P., Fisher-Hoch S.P., McCormick J.B., Georges A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 1999, 5:423-426.
9. Baize S., Leroy E.M., Georges A.J., Georges-Courbot M.C., Capron M., Bedjabaga I., Lansoud-Soukate J., Mavoungou E. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 2002, 128:163-168.
10. Baize S., Kaplon J., Faure C., Pannetier D., Georges-Courbot M.C., Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 2004, 172:2861-2869.
11. Baize S., Marianneau P., Loth P., Reynard S., Journeaux A., Chevallier M., Tordo N., Deubel V., Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 2009, 83:5890-5903.
12. Barton L.L., Hyndman N.J. Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 2000, 105:E35.
13. Barton L.L., Mets M.B., Beauchamp C.L. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 2002, 187:1715-1716.
14. Behanna H.A., Watterson D.M., Ralay Ranaivo H. Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: a lead compound that attenuates vascular leak. Biochim. Biophys. Acta 2006, 1763:1266-1274.
15. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Amanda Lund S., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006, 69:86-97.
16. Bonneville M., O'Brien R.L., Born W.K. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 2010, 10:467-478.
17. Bordon J., Evans P.S., Propp N., Davis C.E., Redfield R.R., Pauza C.D. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J. Infect. Dis. 2004, 189:1482-1486.
18. Bowen G.S., Calisher C.H., Winkler W.G., Kraus A.L., Fowler E.H., Garman R.H., Fraser D.W., Hinman A.R. Laboratory studies of a lymphocytic choriomeningitis virus outbreak in man and laboratory animals. Am. J. Epidemiol. 1975, 102:233-240.
19. Bowen M.D., Rollin P.E., Ksiazek T.G., Hustad H.L., Bausch D.G., Demby A.H., Bajani M.D., Peters C.J., Nichol S.T. Genetic diversity among Lassa virus strains. J. Virol. 2000, 74:6992-7004.
20. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 2001, 82:1365-1373.
21. Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathol. 2009, 5:e1000455.
22. Buckley S.M., Casals J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 1970, 19:680-691.
23. Buchmeier M.J., Welsh R.M., Dutko F.J., Oldstone M.B. The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv. Immunol. 1980, 30:275-331.
24. Cairo C., Propp N., Hebbeler A.M., Colizzi V., Pauza C.D. The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset. Immunology 2005, 115:197-205.
25. Cajimat M.N., Milazzo M.L., Hess B.D., Rood M.P., Fulhorst C.F. Principal host relationships and evolutionary history of the North American arenaviruses. Virology 2007, 367:235-243.
26. Cajimat M.N., Milazzo M.L., Borchert J.N., Abbott K.D., Bradley R.D., Fulhorst C.F. Diversity among Tacaribe serocomplex viruses (family Arenaviridae) naturally associated with the Mexican woodrat (Neotoma mexicana). Virus Res. 2008, 133:211-217.
27. Callis R.T., Jahrling P.B., DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 1982, 31:1038-1045.
28. Carrion R., Patterson J.L., Johnson C., Gonzales M., Moreira C.R., Ticer A., Brasky K., Hubbard G.B., Moshkoff D., Zapata J., Salvato M.S., Lukashevich I.S. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007, 25:4093-4102.
29. Carroll E.E., Hammamieh R., Chakraborty N., Phillips A.T., Miller S.A., Jett M. Altered gene expression in asymptomatic SHIV-infected rhesus macaques (Macacca mulatta). Virol. J. 2006, 3:74.
30. Cashman K.A., Smith M.A., Twenhafel N.A., Larson R.A., Jones K.F., Allen R.D., Dai D., Chinsangaram J., Bolken T.C., Hruby D.E., Amberg S.M., Hensley L.E., Guttieri M.C. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011, 90:70-79.
31. Childs J.E., Glass G.E., Ksiazek T.G., Rossi C.A., Oro J.G., Leduc J.W. Human-rodent contact and infection with lymphocytic choriomeningitis and Seoul viruses in an inner-city population. Am. J. Trop. Med. Hyg. 1991, 44:117-121.
32. Childs J.E., Glass G.E., Korch G.W., Ksiazek T.G., Leduc J.W. Lymphocytic choriomeningitis virus infection and house mouse (Mus musculus) distribution in urban Baltimore. Am. J. Trop. Med. Hyg. 1992, 47:27-34.
33. Cornu T.I., de la Torre J.C. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J. Virol. 2001, 75:9415-9426.
34. Cummins D., Bennett D., Fisher-Hoch S.P., Farrar B., McCormick J.B. Electrocardiographic abnormalities in patients with Lassa fever. J. Trop. Med. Hyg. 1989, 92:350-355.
35. Cummins D., Fisher-Hoch S.P., Walshe K.J., Mackie I.J., McCormick J.B., Bennett D., Perez G., Farrar B., Machin S.J. A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br. J. Haematol. 1989, 72:543-548.
36. Danes L., Benda R., Fuchsova M. Experimental inhalation infection of monkeys of the Macacus Cynomolgus and Macacus Rhesus species with the virus of lymphocytic choriomeningitis (We). Bratisl. Lek. Listy 1963, 2:71-79.
37. Deibel R., Woodall J.P., Decher W.J., Schryver G.D. Lymphocytic choriomeningitis virus in man. Serologic evidence of association with pet hamsters. JAMA 1975, 232:501-504.
38. Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albarino C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathol. 2008, 4:e1000047.
39. De Lorenzo M.S., Yamaguchi K., Subbaramaiah K., Dannenberg A.J. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism. Clin. Cancer Res. 2003, 9:5036-5043.
40. Di Simone C., Zandonatti M.A., Buchmeier M.J. Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology 1994, 198:455-465.
41. Djavani M., Lukashevich I.S., Sanchez A., Nichol S.T., Salvato M.S. Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End. Virology 1997, 235:414-418.
42. Djavani M., Lukashevich I.S., Salvato M.S. Sequence comparison of the large genomic RNA segments of two strains of lymphocytic choriomeningitis virus differing in pathogenic potential for guinea pigs. Virus Genes 1998, 17:151-155.
43. Djavani M., Topisirovic I., Zapata J.C., Sadowska M., Yang Y., Rodas J., Lukashevich I.S., Bogue C.W., Pauza C.D., Borden K.L., Salvato M.S. The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. J. Virol. 2005, 79:2461-2473.
44. Djavani M.M., Crasta O.R., Zapata J.C., Fei Z., Folkerts O., Sobral B., Swindells M., Bryant J., Davis H., Pauza C.D., Lukashevich I.S., Hammamieh R., Jett M., Salvato M.S. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 2007, 81:7960-7973.
45. Djavani M., Crasta O.R., Zhang Y., Zapata J.C., Sobral B., Lechner M.G., Bryant J., Davis H., Salvato M.S. Gene expression in primate liver during viral hemorrhagic fever. Virol. J. 2009, 6:20.
46. Doherty P.C., Zinkernagel R.M. T-cell-mediated immunopathology in viral infections. Transplant. Rev. 1974, 19:89-120.
47. Doherty P.C., Bowern N.A., Dixon J.E., Allan J.E. Characteristics of the inflammatory process in murine lymphocytic choriomeningitis. Med. Microbiol. Immunol. 1986, 175:193-195.
48. Downs W.G., Anderson C.R., Spence L., Aitken T.H.G., Greenhall A.H. Tacaribe virus: a new agent isolated from Artibeus bats and mosquitos in Trinidad, West Indies. Am. J. Trop. Med. Hyg. 1963, 12:640-646.
49. Dubois C., Hengerer B., Mattes H. Identification of a potent agonist of the orphan nuclear receptor Nurr1. Chem. Med. Chem. 2006, 1:955-958.
50. Emonet S., Retornaz K., Gonzalez J.P., de Lamballerie X., Charrel R.N. Mouse-to-human transmission of variant lymphocytic choriomeningitis virus. Emerg. Infect. Dis. 2007, 13:472-475.
51. Ernst E., Koenig W. Fibrinogen and cardiovascular risk. Vasc. Med. 1997, 2:115-125.
52. Feldmann H., Bugany H., Mahner F., Klenk H.D., Drenckhahn D., Schnittler H.J. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 1996, 70:2208-2214.
53. Fisher-Hoch S.P., Mitchell S.W., Sasso D.R., Lange J.V., Ramsey R., McCormick J.B. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 1987, 155:465-474.
54. Fisher-Hoch S.P., McCormick J.B., Sasso D., Craven R.B. Hematologic dysfunction in Lassa fever. J. Med. Virol. 1988, 26:127-135.
55. Fisher-Hoch S.P. Arenavirus Pathophysiology. The Arenaviruses 1993, Plenum Press, New York, (pp. 299-323).
56. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for Lassa fever. J. Virol. 2000, 74:6777-6783.
57. Fisher-Hoch S.P., McCormick J.B. Lassa fever vaccine. Expert Rev. Vaccines 2004, 3:189-197.
58. Fischer S.A., Graham M.B., Kuehnert M.J., Kotton C.N., Srinivasan A., Marty F.M., Comer J.A., Guarner J., Paddock C.D., DeMeo D.L., Shieh W.J., Erickson B.R., Bandy U., DeMaria A., Davis J.P., Delmonico F.L., Pavlin B., Likos A., Vincent M.J., Sealy T.K., Goldsmith C.S., Jernigan D.B., Rollin P.E., Packard M.M., Patel M., Rowland C., Helfand R.F., Nichol S.T., Fishman J.A., Ksiazek T., Zaki S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354:2235-2249.
59. Fu X., Gong M.C., Jia T., Somlyo A.V., Somlyo A.P. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998, 440:183-187.
60. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82:95-102.
61. Garcia C.C., Djavani M., Topisirovic I., Borden K.L., Salvato M.S., Damonte E.B. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J. Gen. Virol. 2006, 87:1217-1228.
62. Genovesi E.V., Peters C.J. Susceptibility of inbred Syrian golden hamsters (Mesocricetus auratus) to lethal disease by lymphocytic choriomeningitis virus. Proc. Soc. Exp. Biol. Med. 1987, 185:250-261.
63. Gilden D.H., Cole G.A., Nathanson N. Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers. J. Exp. Med. 1972, 135(4):874-889. (Apr 1).
64. Gonder E., Eddy G. Indirect immunofluorescence, serum neutralization, and viremia responses of rhesus monkeys (Macaca mulatta) to Machupo virus. J. Med. Virol. 1986, 19:187-192.
65. Gonzalez P.H., Laguens R.P., Frigerio M.J., Calello M.A., Weissenbacher M.C. Junin virus infection of Callithrix jacchus: pathologic features. Am. J. Trop. Med. Hyg. 1983, 32:417-423.
66. Gombart A.F., Saito T., Koeffler H.P. Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics 2009, 10:321.
67. Gowen B.B., Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 2008, 78:79-90.
68. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3:e3725.
69. Gowen B.B., Julander J.G., London N.R., Wong M.H., Larson D., Morrey J.D., Li D.Y., Bray M. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J. 2010, 7:240.
70. Green D.E., Mahlandt B.G., McKee K.T. Experimental Argentine hemorrhagic fever in rhesus macaques: virus-specific variations in pathology. J. Med. Virol. 1987, 22:113-133.
71. Gunther S., Hoofd G., Charrel R., Roser C., Becker-Ziaja B., Lloyd G., Sabuni C., Verhagen R., van der Groen G., Kennis J., Katakweba A., Machang'u R., Makundi R., Leirs H. Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. Emerg. Infect. Dis. 2009, 15:2008-2012.
72. Hinman A.R., Fraser D.W., Douglas R.G., Bowen G.S., Kraus A.L., Winkler W.G., Rhodes W.W. Outbreak of lymphocytic choriomeningitis virus infections in medical center personnel. Am. J. Epidemiol. 1975, 101:103-110.
73. Hoang L.T., Lynn D.J., Henn M., Birren B.W., Lennon N.J., Le P.T., Duong K.T., Nguyen T.T., Mai L.N., Farrar J.J., Hibberd M.L., Simmons C.P. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J. Virol. 2010, 84:12982-12994.
74. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57:976-983.
75. Jahrling P.B., Hesse R.A., Eddy G.A., Johnson K.M., Callis R.T., Stephen E.L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141:580-589.
76. Jahrling P.B., Peters C.J., Stephen E.L. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 1984, 149:420-427.
77. Jahrling P.B., Peters C.J. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect. Immun. 1984, 44:528-533.
78. Johnson K.M., McCormick J.B., Webb P.A., Smith E.S., Elliott L.H., King I.J. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 1987, 155:456-464.
79. Johnson A.T., Wang L., Standeven A.M., Escobar M., Chandraratna R.A. Synthesis and biological activity of high-affinity retinoic acid receptor antagonists. Bioorg. Med. Chem. 1999, 7:1321-1338.
80. Johnson A.T., Wang L., Gillett S.J., Chandraratna R.A. High affinity retinoic acid receptor antagonists: analogs of AGN 193109. Bioorg. Med. Chem. Lett. 1999, 9:573-576.
81. Kagi D., Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 1996, 8:472-477.
82. Kiley M.P., Lange J.V., Johnson K.M. Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 1979, 2:738.
83. Kenyon R.H., McKee K.T., Zack P.M., Rippy M.K., Vogel A.P., York C., Meegan J., Crabbs C., Peters C.J. Aerosol infection of rhesus macaques with Junin virus. Intervirology 1992, 33:23-31.
84. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
85. Landsteiner K., Popper E. Uebertragung der Poliomyelitis acuta auf Affen. Z. immunitatsforsch. 1909, 2:377-390.
86. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82:10768-10775.
87. Lecompte E., ter Meulen J., Emonet S., Daffis S., Charrel R.N. Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 2007, 364:178-183.
88. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283:18734-18742.
89. Lee A.M., Rojek J.M., Gundersen A., Stroher U., Juteau J.M., Vaillant A., Kunz S. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 2008, 372:107-117.
90. Lehmann-Grube F. Portraits of viruses: Arenaviruses. Intervirology 1984, 22:121-145.
91. Leyssen P., De Clercq E., Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 2008, 78:9-25.
92. Li H., Luo K., Pauza C.D. TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells. J. Immunol. 2008, 10:7131-7137.
93. Linero F.N., Scolaro L.A. Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junin virus replication in vitro. Virus Res. 2009, 145:166-170.
94. Lopez N., Jacamo R., Franze-Fernandez M.T. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 2001, 75:12241-12251.
95. Lukashevich I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188:600-605.
96. Lukashevich I.S., Djavani M., Shapiro K., Sanchez A., Ravkov E., Nichol S.T., Salvato M.S. The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J. Gen. Virol. 1997, 78(Pt 3):547-551.
97. Lukashevich I.S., Maryankova R., Vladyko A.S., Nashkevich N., Koleda S., Djavani M., Horejsh D., Voitenok N.N., Salvato M.S. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J. Med. Virol. 1999, 59:552-560.
98. Lukashevich I.S., Djavani M., Rodas J.D., Zapata J.C., Usborne A., Emerson C., Mitchen J., Jahrling P.B., Salvato M.S. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 2002, 67:171-186.
99. Lukashevich I.S., Tikhonov I., Rodas J.D., Zapata J.C., Yang Y., Djavani M., Salvato M.S. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J. Virol. 2003, 77:1727-1737.
100. Lukashevich I.S., Rodas J.D., Tikhonov I.I., Zapata J.C., Yang Y., Djavani M., Salvato M.S. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch. Virol. 2004, 149:2319-2336.
101. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J.C., Brasky K., Geiger R., Hubbard G.B., Bryant J., Salvato M.S. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia Viruses. J. Virol. 2005, 79:13934-13942.
102. Lukashevich I.S., Carrion R., Patterson J., Mansfield K., Brasky K., Zapata J.C., Cairo C., Goicochea M., Gonzales M., Ticer A., Bryant J., Davis H., Hammamieh R., Mayda M., Jett M., Salvato M.S. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26:5246-5254.
103. Mahanty S., Bausch D.G., Thomas R.L., Goba A., Bah A., Peters C.J., Rollin P.E. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 2001, 183:1713-1721.
104. Martín V., Abia D., Domingo E., Grande-Pérez A. An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J. Gen. Virol. 2010, 91(Pt 4):990-1003.
105. Martinez-Peralta L.A., Laguens M., Ponzinibbio C., Laguens R.P. Infection of guinea pigs with two strains of lymphocytic choriomeningitis virus. Medicina (Buenos Aires) 1990, 50:225-229.
106. McCormick J.B., Walker D.H., King I.J., Webb P.A., Elliott L.H., Whitfield S.G., Johnson K.M. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am. J. Trop. Med. Hyg. 1986, 35:401-407.
107. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314:20-26.
108. McKee K.T., Mahlandt B.G., Maiztegui J.I., Eddy G.A., Peters C.J. Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J. Infect. Dis. 1985, 152(1):218-221.
109. McKee K.T., Mahlandt B.G., Maiztegui J.I., Green D.E., Peters C.J. Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaques. J. Med. Virol. 1987, 22:99-111.
110. McKee K.T., Oro J.G., Kuehne A.I., Spisso J.A., Mahlandt B.G. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992, 34:154-163.
111. McKee K.T., Oro J.G., Kuehne A.I., Spisso J.A., Mahlandt B.G. Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am. J. Trop. Med. Hyg. 1993, 48:403-411.
112. McLeod C.G., Stookey J.L., White J.D., Eddy G.A., Fry G.A. Pathology of Bolivian hemorrhagic fever in the African green monkey. Am. J. Trop. Med. Hyg. 1978, 27:822-826.
113. Milazzo M.L., Cajimat M.N., Haynie M.L., Abbott K.D., Bradley R.D., Fulhorst C.F. Diversity among Tacaribe serocomplex viruses (family Arenaviridae) naturally associated with the white-throated woodrat (Neotoma albigula) in the southwestern United States. Vector Borne Zoonotic Dis. 2008, 8:523-540.
114. Mills J.N., Ellis B.A., McKee K.T., Calderon G.E., Maiztegui J.I., Nelson G.O., Ksiazek T.G., Peters C.J., Childs J.E. A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am. J. Trop. Med. Hyg. 1992, 47:749-763.
115. Montali R.J., Connolly B.M., Armstrong D.L., Scanga C.A., Holmes K.V. Pathology and immunohistochemistry of callitrichid hepatitis, an emerging disease of captive New World primates caused by lymphocytic choriomeningitis virus. Am. J. Pathol. 1995, 147:1441-1449.
116. Moshkoff D.A., Salvato M.S., Lukashevich I.S. Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 2007, 34:169-176.
117. Muller S., Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob. Agents Chemother. 2007, 51:2215-2218.
118. Nansen A., Jensen T., Christensen J.P., Andreasen S.O., Röpke C., Marker O., Thomsen A.R. Compromised virus control and augmented perforin-mediated immunopathology in IFN-gamma-deficient mice infected with lymphocytic choriomeningitis virus. J. Immunol. 1999, 163:6114-6122.
119. NIH guidelines Sept 2009. as of Nov 2010. http://oba.od.nih.gov/rdna/nih_guidelines_oba.html.
120. Oldstone M.B. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr. Top. Microbiol. Immunol. 2002, 263:83-117.
121. Oehen S., Hengartner H., Zinkernagel R.M. Vaccination for disease. Science 1991, 251:195-198.
122. Palacios G., Druce J., Du L., Tran T., Birch C., Briese T., Conlan S., Quan P.L., Hui J., Marshall J., Simons J.F., Egholm M., Paddock C.D., Shieh W.J., Goldsmith C.S., Zaki S.R., Catton M., Lipkin W.I. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 2008, 358:991-998.
123. Palacios G., Savji N., Hui J., Travassos da Rosa A., Popov V., Briese T., Tesh R., Lipkin W.I. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J. Gen. Virol. 2010, 91:1315-1324.
124. Park J.Y., Peters C.J., Rollin P.E., Ksiazek T.G., Katholi C.R., Waites K.B., Gray B., Maetz H.M., Stephensen C.B. Age distribution of lymphocytic choriomeningitis virus serum antibody in Birmingham, Alabama: evidence of a decreased risk of infection. Am. J. Trop. Med. Hyg. 1997, 57:37-41.
125. Parker J.C., Igel H.J., Reynolds R.K., Lewis A.M., Rowe W.P. Lymphocytic choriomeningitis virus infection in fetal, newborn, and young adult Syrian hamsters (Mesocricetus auratus). Infect. Immun. 1976, 13:967-981.
126. Perez M., Craven R.C., de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. USA 2003, 100:12978-12983.
127. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20:157-198.
128. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 1987, 134:5-68.
129. Piriyapongsa J., Marino-Ramirez L., Jordan I.K. Origin and evolution of human microRNAs from transposable elements. Genetics 2007, 176:1323-1337.
130. Poonia B., Salvato M.S., Yagita H., Maeda T., Okumura K., Pauza C.D. Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood 2009, 114:1196-1204.
131. Poonia B., Pauza C.D., Salvato M.S. Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology 2009, 6:91.
132. Radomsky C.L., Levine N. Thalidomide. Dermatol. Clin. 2001, 19:87-103.
133. Radoshitzky S.R., Dong L., Chi X., Clester J.C., Retterer C., Spurgers K., Kuhn J.H., Sandwick S., Ruthel G., Kota K., Boltz D., Warren T., Kranzusch P.J., Whelan S.P., Bavari S. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 2010, 84:10569-10580.
134. Rai S.K., Cheung D.S., Wu M.S., Warner T.F., Salvato M.S. Murine infection with lymphocytic choriomeningitis virus following gastric inoculation. J. Virol. 1996, 70:7213-7218.
135. Rai S.K., Micales B.K., Wu M.S., Cheung D.S., Pugh T.D., Lyons G.E., Salvato M.S. Timed appearance of lymphocytic choriomeningitis virus after gastric inoculation of mice. Am. J. Pathol. 1997, 151:633-639.
136. Reiserova L., Kaluzova M., Kaluz S., Willis A.C., Zavada J., Zavodska E., Zavadova Z., Ciampor F., Pastorek J., Pastorekova S. Identification of MaTu-MX agent as a new strain of lymphocytic choriomeningitis virus (LCMV) and serological indication of horizontal spread of LCMV in human population. Virology 1999, 257:73-83.
137. Riedel D.J., Sajadi M.M., Armstrong C.L., Cummings J.S., Cairo C., Redfield R.R., Pauza C.D. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 2009, 23:1955-1964.
138. Rivers T.M., Scott T.F. Meningitis in man caused by a filterable virus. Science 1935, 81:439-440.
139. Rivers T.M., Scott T.F. meningitis in man caused by a filterable virus: Ii. Identification of the etiological agent. J. Exp. Med. 1936, 63:415-432.
140. Riviere Y., Oldstone M.B. Genetic reassortants of lymphocytic choriomeningitis virus: unexpected disease and mechanism of pathogenesis. J. Virol. 1986, 59:363-368.
141. Roberts P.J., Cummins D., Bainton A.L., Walshe K.J., Fisher-Hoch S.P., McCormick J.B., Gribben J.G., Machin S.J., Linch D.C. Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. Br. J. Haematol. 1989, 73:152-157.
142. Rodas J.D., Lukashevich I.S., Zapata J.C., Cairo C., Tikhonov I., Djavani M., Pauza C.D., Salvato M.S. Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J. Med. Virol. 2004, 72:424-435.
143. Rodas J.D., Cairo C., Djavani M., Zapata J.C., Ruckwardt T., Bryant J., Pauza C.D., Lukashevich I.S., Salvato M.S. Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem. Inst. Oswaldo Cruz 2009, 104:583-591.
144. Rojek J.M., Pasqual G., Sanchez A.B., Nguyen N.T., de la Torre J.C., Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 2010, 84:573-584.
145. Rowe W.P., Pugh W.E., Webb P.A., Peters C.J. Serological relationship of the Tacaribe complex of viruses to lymphocytic choriomeningitis virus. J. Virol. 1970, 5:289-292.
146. Rubins K.H., Hensley L.E., Wahl-Jensen V., Daddario DiCaprio K.M., Young H.A., Reed D.S., Jahrling P.B., Brown P.O., Relman D.A., Geisbert T.W. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol. 2007, 8:R174.
147. Ruggiero H.R., Parodi A.S., Ruggiero H.G., Mettler N., Boxaca M., Deguerrero A.L., Cintora A., Magnoni C., Milani H., Maglio F., Gonzalezcambaceres C., Astarloa L., Squassi G., Fernandez D., Giacosa V.A. Argentine Hemorrhagic Fever. I. Period of incubation and invasion. Rev. Asoc. Med. Argent. 1964, 78:221-226.
148. Samoilovich S.R., Pecci Saavedra J., Frigerio M.J., Weissenbacher M.C. Nasal and intrathalamic inoculations of primates with Tacaribe virus: protection against Argentine hemorrhagic fever and absence of neurovirulence. Acta Virol. 1984, 28:277-281.
149. Samoilovich S.R., Calello M.A., Laguens R.P., Weissenbacher M.C. Long-term protection against Argentine hemorrhagic fever in Tacaribe virus infected marmosets: virologic and histopathologic findings. J. Med. Virol. 1988, 24:229-236.
150. Salvato M.S., Shimomaye E.M. The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology 1989, 173:1-10.
151. Salvato M.S., Clegg J.C.S., Buchmeier M.J., Charrel R.N., Gonzalez J.-P., Lukashevich I.S., Peters C.J., Rico-Hesse R., Romanowski V. Arenaviridae. Virus Taxonomy, VIIIth Report of the ICTV 2004, 725-733. Elsevier/Academic Press, London. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
152. Salvato M.S., Yin C.C., Yagita H., Maeda T., Okumura K., Tikhonov I., Pauza C.D. Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL. Clin. Dev. Immunol. 2007, 2007:93462.
153. Salvato M.S., Lukashevich I.S. " Vaccines Against Lassa Fever." New Generation Vaccines 2009, Marcel Dekker, Inc., NY. L. Myron (Ed.).
154. Salvato M.S., Clegg J.C.S., Buchmeier M.J., Charrel R.N., Gonzalez J.-P., Lukashevich I.S., Peters C.J., Rico-Hesse R., Romanowski V. Arenaviridae. Virus Taxonomy, XIth Report of the ICTV 2012, 683-691. Elsevier/Academic Press, London. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
155. Sanchez A.B., Perez M., Cornu T., de la Torre J.C. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2005, 79:11071-11081.
156. Schnittler H.J., Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr. Top. Microbiol. Immunol. 1999, 235:175-204.
157. Sepulveda C.S., Garcia C.C., Damonte E.B. Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Res. 2010, 87:329-337.
158. Shah W.A., Peng H., Carbonetto S. Role of non-raft cholesterol in lymphocytic choriomeningitis virus infection via alpha-dystroglycan. J. Gen. Virol. 2006, 87:673-678.
159. Skinner H.H., Knight E.H. The potential role of Syrian hamsters and other small animals as reservoirs of lymphocytic choriomeningitis virus. J. Small Anim. Pract. 1979, 20:145-161.
160. Smith A.L., Paturzo F.X., Gardner E.P., Morgenstern S., Cameron G., Wadley H. Two epizootics of lymphocytic choriomeningitis virus occurring in laboratory mice despite intensive monitoring programs. Can. J. Comp. Med. 1984, 48:335-337.
161. Smith A.L., Singleton G.R., Hansen G.M., Shellam G. A serologic survey for viruses and Mycoplasma pulmonis among wild house mice (Mus domesticus) in southeastern Australia. J. Wildl. Dis. 1993, 29:219-229.
162. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 2008, 14:1357-1362.
163. Stephen E.L., Jahrling P.B. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1979, 1:268-269.
164. Stephenson E.H., Larson E.W., Dominik J.W. Effect of environmental factors on aerosol-induced Lassa virus infection. J. Med. Virol. 1984, 14:295-303.
165. Taylor P.C. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern. Med. 2003, 42:15-20.
166. Terrell T.G., Stookey J.L., Eddy G.A., Kastello M.D. Pathology of Bolivian hemorrhagic fever in the rhesus monkey. Am. J. Pathol. 1973, 73:477-494.
167. Theiler M., Smith H.H. The use of Yellow Fever Virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 65:787-800.
168. Traub E. The epidemiology of lymphocytic choriomeningitis in white mice. J. Exp. Med. 1936, 64:183-200.
169. Vela E.M., Knostman K.A., Mott J.M., Warren R.L., Garver J.N., Vela L.J., Stammen R.L. Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model. Antiviral Res. 2010, 87:318-328.
170. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., Ahmed R., Amara R.R. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
171. Vieth S., Drosten C., Lenz O., Vincent M., Omilabu S., Hass M., Becker-Ziaja B., ter Meulen J., Nichol S.T., Schmitz H., Gunther S. RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1253-1264.
172. Vilcheze C., Morbidoni H.R., Weisbrod T.R., Iwamoto H., Kuo M., Sacchettini J.C., Jacobs W.R. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 2000, 182:4059-4067.
173. Voevodin A.F., Marx P.A. In Simian Virology 2009, Wiley-Blackwell, Singapore, (pp. 25-27).
174. Wagner F.S., Eddy G.A., Brand O.M. The African green monkey as an alternate primate host for studying Machupo virus infection. Am. J. Trop. Med. Hyg. 1977, 26:159-162.
175. Wallace M., Pauza C.D., Salvato M.S. Macaque models for early immunosuppression and T cell loss during acute immunodeficiency virus infections. J. Biol. Regul. Homeost. Agents 2000, 15:304-307.
176. Walker D.H., McCormick J.B., Johnson K.M., Webb P.A., Komba-Kono G., Elliott L.H., Gardner J.J. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 1982, 107:349-356.
177. Walker D.H., Johnson K.M., Lange J.V., Gardner J.J., Kiley M.P., McCormick J.B. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 1982, 146:360-368.
178. Whitby L.R., Lee A.M., Kunz S., Oldstone M.B., Boger D.L. Characterization of lassa virus cell entry inhibitors: determination of the active enantiomer by asymmetric synthesis. Bioorg. Med. Chem. Lett. 2009, 19:3771-3774.
179. Weber L.P., Seto M., Sasaki Y., Sward K., Walsh M.P. The involvement of protein kinase C in myosin phosphorylation and force development in rat tail arterial smooth muscle. Biochem. J. 2000, 352(Pt 2):573-582.
180. Weissenbacher M.C., Coto C.E., Calello M.A., Rondinone S.N., Damonte E.B., Frigerio M.J. Cross-protection in nonhuman primates against Argentine hemorrhagic fever. Infect. Immun. 1982, 35:425-430.
181. Weissenbacher M.C., Calello M.A., Merani M.S., McCormick J.B., Rodriguez M. Therapeutic effect of the antiviral agent ribavirin in Junin virus infection of primates. J. Med. Virol. 1986, 20:261-267.
182. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 1993, 110:245-252.
183. Wolf M.C., Freiberg A.N., Zhang T., Akyol-Ataman Z., Grock A., Hong P.W., Li J., Watson N.F., Fang A.Q., Aguilar H.C., Porotto M., Honko A.N., Damoiseaux R., Miller J.P., Woodson S.E., Chantasirivisal S., Fontanes V., Negrete O.A., Krogstad P., Dasgupta A., Moscona A., Hensley L.E., Whelan S.P., Faull K.F., Holbrook M.R., Jung M.E., Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. USA 2010, 107:3157-3162.
184. Yang Z., Delgado R., Xu L., Todd R.F., Nabel E.G., Sanchez A., Nabel G.J. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998, 279:1034-1037.
185. Yang K., Bai H., Ouyang Q., Lai L., Tang C. Finding multiple target optimal intervention in disease-related molecular network. Mol. Syst. Biol. 2008, 4:228.
186. York J., Dai D., Amberg S.M., Nunberg J.H. PH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 2008, 82:10932-10939.
187. York J., Berry J.D., Stroher U., Li Q., Feldmann H., Lu M., Trahey M., Nunberg J.H. An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion. J. Virol. 2010, 84:6119-6129.
188. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974, 248:701-702.